When the anti-obesity drug space is discussed, the names Arena (NASDAQ:ARNA) and Vivus (NASDAQ:VVUS) are often the first mentioned. Orexigen (NASDAQ:OREX) is often mentioned as an afterthought. The reasoning behind this is relatively simple. Vivus and Arena were the first two anti-obesity drugs to gain FDA approval in over a decade, and both have their products on the market. Arena has the recently launched Belviq, and Vivus launched Qsymia last Fall. In contrast, Orexigen's Contrave is still in the FDA approval process and in hopes of getting to the market sometime next year.
If Orexigen is the third player to the game what makes it attractive? That answer is pretty complex and...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|